Maternal and Fetal Health Company Raydiant Oximetry Secures $7.5M in Oversubscribed Series A Extension Round

Raydiant Oximetry, a clinical-stage medical device company focused on improving outcomes for mothers and babies during childbirth has closed an oversubscribed $7.5 million Series A3 extension round. The round was led by Cross-Border Impact Ventures (CBIV), a VC fund focused on the health of women and children worldwide. The round also included participation from RH Capital, Global Health Impact Fund, VCapital, and the March of Dimes Innovation Fund.

“We are proud to lead this oversubscribed round with such an aligned group of co-investors. The company’s products have tremendous potential to generate strong returns for our fund while saving and improving the lives of women and children in multiple markets globally,” says Annie Thériault, Managing Partner at CBIV. “We have been following Raydiant Oximetry for over four years and are continuously impressed with the team’s ability to innovate and execute.”